A recent ongoing phase 2 study (NCT04896385), currently in the recruitment stage, aims to investigating the mechanism of action of ruxolitinib cream for the treatment of vitiligo by evaluating the changes in immune biomarkers, including CXCL10. The gene discussed is CXCL10; the disease is vitiligo.